GET DAILY SIGNALSWhy Is agilon health, inc. (AGL) Stock Up +11.72% Today?
Key Takeaways
- agilon health (AGL) shares jumped roughly +11.72% in Wednesday's session, trading near $107.51 versus a prior close of $96.23.
- The move was driven by third-quarter 2026 earnings that crushed Wall Street expectations, including a swing to profitability and raised full-year guidance.
- Secondary support came from a sharp improvement in adjusted EBITDA and upbeat commentary on 2027 membership growth.
- The advance outpaced the broader market and reflected renewed investor confidence in the company's value-based senior care model.
- Traders are now watching for analyst estimate revisions and the company's upcoming November 17 investor event.
- For more detail on valuation, results, and outlook, explore the dedicated Price Targets, Earnings, and Forecast pages.
- You can also discover the strongest AI-powered strategies for this and thousands of other tickers by exploring Trending AI Robots.
Opening Summary
agilon health, inc. (AGL), a Westerville, Ohio-based healthcare services company that partners with physician groups to transition senior care toward a value-based "Total Care Model," surged on Wednesday. Shares climbed approximately 11.72% to about $107.51, up from the prior session's close of $96.23, confirming a decisive move to the upside. The immediate catalyst cited by markets was the company's third-quarter 2026 earnings report, released after Tuesday's close, which delivered a dramatic beat on earnings, a return to operating profitability, and an upgraded full-year outlook.
Earnings Results: A Major Beat and Swing to Profitability
The dominant driver behind the rally was a quarterly report that far exceeded expectations. agilon health posted adjusted earnings of roughly $1.97 per share, compared with consensus estimates that had anticipated a loss. On a GAAP basis, the company swung to a profit from a significant net loss in the year-ago period. Revenue rose about 5.9% year over year to approximately $1.52 billion, also topping analyst forecasts. The results marked a stark turnaround in operating performance, with adjusted EBITDA coming in near $64 million versus a negative $91 million a year earlier.
Raised Guidance and Improving Cost Trends
Investor enthusiasm was reinforced by management's decision to raise full-year 2026 guidance. The company lifted its revenue outlook and, more notably, increased its adjusted EBITDA forecast to a midpoint near $150 million—a substantial upward revision from the prior range. Underpinning the improvement was a meaningful decline in the medical services expense ratio (MSER), which fell to roughly 88.5% from about 104.0% a year earlier, helped by favorable claims development and payer contract improvements. Executives also signaled expectations for 40–50% growth in accountable care organization (ACO) membership in 2027, supporting the longer-term growth narrative.
Sector and Market Context
The advance aligned with broader investor appetite for healthcare services names showing margin recovery, even as the company flagged a 10% year-over-year decline in Medicare Advantage membership to roughly 454,000—a headwind tied to previously announced market exits and a deliberate focus on profitable contracts. Despite that caution, the magnitude of the earnings surprise and the margin inflection overshadowed membership softness. The stock's move reflected company-specific fundamentals more than broad index action, with AGL trading sharply higher as the market digested the beat and upgraded outlook.
Market Context and Trading Activity
Trading activity reflected strong conviction, with the shares gapping higher and holding gains through the session. The move pushed the stock well above recent trading ranges and prior resistance, signaling a technical breakout driven by the earnings catalyst. The rally came on the heels of a period of elevated volatility for the name, and the post-earnings surge suggested short-covering and fresh institutional buying as the company demonstrated a clearer path toward sustained profitability.
What Comes Next for AGL
Looking ahead, investors will focus on whether analysts revise their estimates upward in response to the beat and guidance raise. The company has scheduled a virtual investor event on November 17, 2026, where management is expected to detail its clinical strategy and technology platform—an update that could further shape sentiment. Key considerations include the pace of ACO membership growth, continued improvement in medical cost trends, and the company's cash position, which stood at roughly $312 million in cash and marketable securities at quarter-end. Risks remain, including elevated medical cost ratios, a modest 2027 contracting benefit relative to 2026, and limited near-term expansion into new markets until 2028.
Trending AI Robots
For traders seeking a systematic edge, Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore approaches that align with their own objectives. Consider exploring the page to see which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AGL's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for AGL turned positive on November 04, 2026. Looking at past instances where AGL's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 62 cases where AGL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on AGL as a result. In 66 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
AGL moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for AGL crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
Following a +11.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where AGL advanced for three days, in 229 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 156 of 183 cases where AGL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AGL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
AGL broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.102) is normal, around the industry mean (204.059). P/E Ratio (-6.801) is within average values for comparable stocks, (18.581). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.091) among similar stocks. P/S Ratio (0.253) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. AGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AGL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement